{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T22:56:16Z","timestamp":1789253776946,"version":"build-2803163510"},"reference-count":40,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High-dose melphalan supported by autologous transplantation has been the standard of care for eligible patients with newly diagnosed multiple myeloma (MM) for &amp;gt;25 years. Several randomized clinical trials have recently reaffirmed the strong position of transplantation in the era of proteasome inhibitors and immunomodulatory drugs combinations, demonstrating a significant reduction of progression or death in comparison with strategies without transplantation. Immunotherapy is currently changing the paradigm of MM management, and daratumumab is the first-in-class human monoclonal antibody targeting CD38 approved in the setting of newly diagnosed MM. Quadruplets have become the new standard in transplantation programs, but outcomes remain heterogeneous, with various response depth and duration. The development of sensitive and specific tools for disease prognostication allows the consideration of strategies adaptive to dynamic risk. This review discusses the different options available for the treatment of transplantation-eligible patients with MM in frontline setting.<\/jats:p>","DOI":"10.1182\/blood.2020008735","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T21:10:47Z","timestamp":1637183447000},"page":"2882-2888","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["How I treat frontline transplantation-eligible multiple myeloma"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"first","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, and"},{"name":"Centre de Recherches en Canc\u00e9rologie de Toulouse, Universit\u00e9 de Toulouse, Universit\u00e9 Toulouse III Paul Sabatier, INSERM, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2022051215233669100_B1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-018-0155-7","article-title":"Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG research project","volume":"8","author":"Usmani","year":"2018","journal-title":"Blood Cancer J."},{"issue":"2","key":"2022051215233669100_B2","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere."},{"key":"2022051215233669100_B3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-137575","article-title":"Upfront autologous hematopoietic stem-cell transplantation improves overall survival in comparison with bortezomib-based intensification therapy in newly diagnosed multiple myeloma: long-term follow-up analysis of the randomized phase 3 EMN02\/HO95 study [abstract]","volume":"136","author":"Cavo","year":"2020","journal-title":"Blood."},{"key":"2022051215233669100_B4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial [abstract]","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood."},{"key":"2022051215233669100_B5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-136907","article-title":"Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomized Forte trial [abstract]","volume":"136","author":"Gay","year":"2020","journal-title":"Blood."},{"issue":"30","key":"2022051215233669100_B6","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol."},{"issue":"24","key":"2022051215233669100_B7","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol."},{"issue":"22","key":"2022051215233669100_B8","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood."},{"issue":"1","key":"2022051215233669100_B9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-thalidomidedexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood."},{"issue":"21","key":"2022051215233669100_B10","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood."},{"key":"2022051215233669100_B11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.8003","article-title":"Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM) [abstract]","volume":"35","author":"Gay","year":"2017","journal-title":"J Clin Oncol."},{"issue":"23","key":"2022051215233669100_B12","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood."},{"issue":"16","key":"2022051215233669100_B13","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol","year":"2019","journal-title":"Blood."},{"issue":"8","key":"2022051215233669100_B14","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol."},{"key":"2022051215233669100_B15","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2018-99-112659","article-title":"Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma [abstract]","volume":"132","author":"Rosinol Dachs","year":"2018","journal-title":"Blood."},{"issue":"10192","key":"2022051215233669100_B16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet."},{"issue":"6","key":"2022051215233669100_B17","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"2022051215233669100_B18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","article-title":"Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM) [abstract]","volume":"38","author":"Hari","year":"2020","journal-title":"J Clin Oncol."},{"issue":"19","key":"2022051215233669100_B19","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med."},{"issue":"19","key":"2022051215233669100_B20","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med."},{"issue":"10","key":"2022051215233669100_B21","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med."},{"issue":"29","key":"2022051215233669100_B22","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022051215233669100_B23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol."},{"issue":"7","key":"2022051215233669100_B24","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3324\/haematol.2020.247130","article-title":"Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial","volume":"106","author":"Jackson","year":"2021","journal-title":"Haematologica."},{"issue":"12","key":"2022051215233669100_B25","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"2022051215233669100_B26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.8538","article-title":"Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA [abstract]","volume":"38","author":"Touzeau","year":"2020","journal-title":"J Clin Oncol."},{"issue":"26","key":"2022051215233669100_B27","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol."},{"key":"2022051215233669100_B28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk Res."},{"issue":"8","key":"2022051215233669100_B29","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3324\/haematol.2020.261842","article-title":"Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib\/thalidomide\/dexamethasone in the phase 3 CASSIOPEIA study","volume":"106","author":"Hulin","year":"2021","journal-title":"Haematologica."},{"issue":"8","key":"2022051215233669100_B30","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood."},{"issue":"12","key":"2022051215233669100_B31","doi-asserted-by":"crossref","first-page":"e874","DOI":"10.1016\/S2352-3026(20)30356-2","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial","volume":"7","author":"Roussel","year":"2020","journal-title":"Lancet Haematol."},{"issue":"2","key":"2022051215233669100_B32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/imt-2020-0266","article-title":"Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison","volume":"13","author":"Moreau","year":"2021","journal-title":"Immunotherapy."},{"issue":"6","key":"2022051215233669100_B33","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol."},{"issue":"10","key":"2022051215233669100_B34","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"issue":"34","key":"2022051215233669100_B35","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1200\/JCO.20.02060","article-title":"Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial","volume":"38","author":"Dimopoulos","year":"2020","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022051215233669100_B36","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","article-title":"Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p","volume":"119","author":"Neben","year":"2012","journal-title":"Blood."},{"issue":"3","key":"2022051215233669100_B37","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia."},{"issue":"19","key":"2022051215233669100_B38","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.18.00776","article-title":"Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma","volume":"37","author":"Perrot","year":"2019","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022051215233669100_B39","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.3324\/haematol.2019.236588","article-title":"Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk","volume":"105","author":"Corre","year":"2020","journal-title":"Haematologica."},{"issue":"8","key":"2022051215233669100_B40","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/19\/2882\/1896511\/bloodbld2020008735c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/19\/2882\/1896511\/bloodbld2020008735c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T18:30:32Z","timestamp":1673807432000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/19\/2882\/482664\/How-I-treat-frontline-transplantation-eligible"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":40,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2022,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008735","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]}}}